Although the exogenous RBP4 treatment didn’t significantly improve the lung function of PA-COPD mice, it alleviated the further decline of FVC and FEV50 caused by rm–IL-17A (Figures 6F, G). This evidence concerns the gene IL17A and chronic obstructive pulmonary disease.